New growth model
Indian pharma majors are facing their toughest year yet in the US, with regulatory clampdown, hostile political environment and falling prices. Is reinvention the answer to their woes?
Kripa Mahalingam - July 26, 2019
Vishnukant Bhutada’s big bet on oncology has catapulted Shilpa Medicare into the global generics space
Shilpa Elizabeth Abraham - June 09, 2017